Centrum 7/6  banner

AstraZeneca’s COVID-19 vaccine is found to be 79% effective

Print Friendly, PDF & Email

NEW YORK — A U.S. trial of AstraZeneca’s coronavirus vaccine found that it completely prevented the worst outcomes from COVID-19. No subjects in the trial reported serious safety issues.

More than 32,000 subjects participated in the trial, the largest yet for the AstraZeneca vaccine. Based on those results, it was 79% effective overall in preventing symptomatic infections. It also offered strong protection for older people, who had not been as well represented in earlier studies.

The company said it will soon seek approval from the Food and Drug Administration, even though the U.S. may not need the vaccine — doses are unlikely to become available before May, when federal officials predict there will be enough doses from the three vaccines that have already been authorized for all U.S. adults. But the results could help the vaccine recover from the safety scare it faced in Europe.


ECRM_06-01-22


Comments are closed.

PP_1170x120_10-25-21